Business context and reporting period
Stepan Company’s Form 10-K covers the fiscal year ended December 31, 2014; it is an annual report, not a standalone fourth-quarter filing. The company makes specialty and intermediate chemicals across Surfactants, Polymers, and Specialty Products. Surfactants represented 67% of 2014 sales, Polymers 29%, and Specialty Products 4%. Approximately 41% of sales were outside the United States.
Key financial metrics
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Net sales | $1,927.2 million | $1,880.8 million | +2% |
| Gross profit | $249.6 million | $281.7 million | -11% |
| Operating income | $90.7 million | $109.2 million | -17% |
| Net income attributable to Stepan | $57.1 million | $72.8 million | -22% |
| Diluted EPS | $2.49 | $3.18 | -22% |
| Operating margin | 4.7% | 5.8% | -1.1 percentage points |
| Operating cash flow | $82.0 million | $150.3 million | Down $68.4 million |
| Capital expenditures | $101.8 million | $92.9 million | +10% |
Consolidated sales increased because higher average selling prices added $131.2 million, partly offset by a $74.0 million impact from lower sales volume and a $10.8 million unfavorable currency effect. Gross margin was approximately 13.0%, versus 15.0% in 2013. Cash and cash equivalents were $85.2 million; working capital was $326.0 million and the current ratio was 2.3. Total debt was $273.9 million, net debt $188.7 million, and total debt-to-capitalization 33.8%. The company paid $0.69 per common share in dividends for the year.
Material changes versus the prior comparable period
- Surfactants sales fell 2% and segment operating income fell 39%. Volume declined 8%, primarily in North America; higher pricing largely reflected increased raw-material costs. Results also faced higher maintenance, freight, and other operating costs.
- Polymers sales increased 14% and segment operating income increased 11%, supported by volume growth and a full year of contribution from the polyester resins business acquired in June 2013. Results included a $2.4 million bad-debt charge for a customer that filed for bankruptcy.
- Specialty Products sales declined 1% and operating income declined 4%; fourth-quarter volume fell 12%, with competitive pricing pressure and unfavorable mix.
- Lower administrative expense, principally a $21.4 million year-over-year reduction in deferred-compensation expense, partly offset the decline in gross profit. A $7.1 million increase in the Maywood environmental remediation estimate and higher legal and environmental costs were offsets.
- Operating cash flow declined as working capital used $46.5 million more cash than in 2013, including increased uses from receivables and inventories. Cash fell by $48.1 million during the year.
Outlook, commentary, risks, and unusual items
Management said it was positioned to re-establish earnings momentum in 2015. It expected benefits from continued Polymers growth, higher functional surfactant volumes, improved operations, recovery of higher freight costs, and lower raw-material prices. North American commodity consumer-product and biodiesel volumes remained challenges. The company forecast 2015 capital expenditures of $120 million to $140 million.
- A proposed acquisition of a 30,000-metric-ton sulfonation facility in Bahia, Brazil, was expected to close in the first or second quarter of 2015, subject to customary conditions. The filing does not provide a purchase price.
- Construction of a replacement China plant was forecast to begin operating in the first half of 2016. Execution, cost overruns, and capacity assumptions are identified risks.
- In January 2015, Stepan sold its specialty polyurethane systems product lines, which had approximately $2.8 million of 2014 sales. It expected a pretax gain of $2.5 million to $3.0 million in first-quarter 2015.
- Fourth-quarter 2014 restructuring and asset-impairment charges totaled $4.0 million. The company recorded a $1.7 million restructuring charge and $2.3 million for asset write-offs, including cancellation of a Singapore expansion project.
- Fourth-quarter customer-claim expense was $3.475 million; discussions and investigations continued, so the ultimate amount could differ. Maywood remediation costs are also uncertain: estimated environmental and legal losses ranged from $21.9 million to $41.8 million, with $22.0 million accrued at year-end.
- The company reported $273.9 million in debt, including $27.0 million of current maturities. Its $125.0 million revolving facility had $20.0 million drawn and $102.3 million available at year-end. Management stated it expected cash, operating cash flow, and committed facilities to fund foreseeable needs and believed it would remain covenant-compliant in 2015. Debt agreements restrict additional borrowing, dividends, and share repurchases.
- Defined-benefit pension plans were underfunded by $43.2 million at year-end, versus $10.1 million in 2013, largely due to lower discount rates, updated mortality assumptions, and investment returns below expectations.
- Key risks include manufacturing outages, raw-material and energy cost volatility, transportation interruptions, competition, foreign-exchange exposure, environmental and product-regulatory liabilities, customer credit risk, and foreign operations. Deloitte issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Whether 2015 earnings improvement materialized, particularly the expected recovery in functional surfactants, freight costs, and raw-material benefits.
- Progress, closing terms, and integration results for the proposed Brazil facility acquisition, and the timing and costs of the China replacement plant.
- Cash conversion and working-capital trends after the 2014 decline in operating cash flow, alongside the elevated capital-spending plan.
- Actual outcomes for the Maywood remediation estimate and customer claims, and whether the Polymer customer bankruptcy produces further credit losses.
- Debt maturities, revolver availability, covenant headroom, and dividend capacity under the debt agreements.
- Whether pension funding status and the associated assumptions change materially, and whether the expected gain from the product-line sale is recorded as forecast.